GAA
REGN icon

Green Alpha Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Green Alpha Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Buy
341
+5
+1% +$3.4K 0.14% 101
2026
Q1 		$260K Sell
336
-45
-12% -$34.5K 0.26% 82
2025
Q4 		$294K Buy
+381
New +$259K 0.27% 88
2025
Q2 		– Sell
-344
Closed -$218K – 110
2025
Q1 		$218K Sell
344
-14
-4% -$9.63K 0.23% 92
2024
Q4 		$255K Sell
358
-24
-6% -$20.1K 0.2% 118
2024
Q3 		$402K Sell
382
-34
-8% -$37.8K 0.32% 99
2024
Q2 		$437K Sell
416
-52
-11% -$50.4K 0.35% 95
2024
Q1 		$450K Buy
468
+7
+2% +$6.66K 0.33% 105
2023
Q4 		$405K Sell
461
-71
-13% -$58.5K 0.29% 119
2023
Q3 		$438K Buy
+532
New +$418K 0.34% 99

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Green Alpha Advisors's REGN Position: Q2 2026 in Review

Green Alpha Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 1.5% in Q2 2026, buying an estimated $3.4K and bringing the position to 341 shares worth $213K. The position accounts for 0.14% of the portfolio, ranked #101.

Green Alpha Advisors first reported a position in REGN in Q3 2023 and has held it in 10 quarters since. The position peaked at $450K in Q1 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Green Alpha Advisors held 341 shares of Regeneron Pharmaceuticals worth $213K as of Q2 2026.
  • Green Alpha Advisors bought 5 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.4K.
  • Regeneron Pharmaceuticals made up 0.14% of Green Alpha Advisors's portfolio in Q2 2026, its #101 holding.
  • Green Alpha Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
  • Green Alpha Advisors's Regeneron Pharmaceuticals position peaked at $450K in Q1 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Green Alpha Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.